Likelihood, two years: 3Possible; to end-2028
Likelihood, ten years: 4Likely; to end-2036
Systemic impact: 3Significant; global
National impact: 4Major; typical highly exposed nation
Onset pace: Months
Duration (acute phase): 5 years
Warning time: Months
Scope: Global
Recovery horizon: Structural
Capability load: Hard 1/3Soft 2/3Economic 1/3; domains loaded High
Concurrency: Standalone; triggers 2 · triggered by 4
Confidence · movement: low; new

Rated at Standard Severe. Event reach: global event (Likelihood is that of the full event: trial confirmation of the effect and licensing that makes treatment affordable in most regions within two years of the results.). Source of scores: model-panel-v0.5. Upside scenario: impact levels measure the scale of change, not loss.

Capture test: results by nation

03Narrative

Dateline: November 2034

The two trials reported within six weeks of each other in the spring of 2028. Together they had followed 64,000 adults in 29 countries for four years. Patients selected by a short panel of blood and urine markers and given a daily combination of off-patent and newly licensed metabolic medicines had 30 per cent fewer heart attacks, strokes, cases of kidney failure and amputations than those given usual care. The effect held across income groups and in both sexes.

The price mattered as much as the result. The rights holders agreed non-exclusive licences covering 140 countries before the end of 2028. By early 2030 manufacturers in India, China, Brazil, Egypt and South Africa were supplying the combination at under US$6 a month. The marker panel ran on equipment that most district laboratories already had.

What followed divided nations by their health systems more than by their income. Where primary care held a register of patients and was paid for keeping them well, eligible adults were called in, tested and started on treatment within months. Community health workers and pharmacists did most of the monitoring, supported by decision software. In those systems avoidable admissions for cardiovascular and diabetic complications were 15 per cent lower in 2034 than in 2029, and disability claims among people aged 50 to 64 had fallen. More women were in paid work, in part because fewer were caring for a relative after a stroke.

Where hospitals were paid by the admission and primary care was thin, the medicines reached pharmacies and went little further. Uptake followed the ability to pay for a consultation. Several middle-income nations recorded a widening gap in cardiovascular deaths between cities and rural districts, and between insured and uninsured workers.

The fiscal effects arrived in a different order from the health effects. Finance ministries booked lower hospital spending slowly, because beds that emptied were filled from waiting lists. Actuaries moved faster. Mortality tables revised in 2032 added about a year to projected life expectancy at 60 in adopting nations, and pension schemes that had assumed otherwise reported larger deficits. Four governments brought forward legislation on pension age. Dialysis operators and cardiac surgery centres closed capacity, and two listed hospital groups restructured their debt.

By late 2034 the question put to health ministers had changed. It was no longer whether the treatment worked or what it cost. It was why a neighbouring nation with a lower income had cut its stroke admissions by a fifth while their own had not moved.

The dateline is illustrative, not a forecast. The narrative is hypothetical; the historical anchors below are real events.

04Summary

Large trials establish that a low-cost combination of metabolic treatments and biomarker-guided prevention reduces major cardiovascular and diabetes complications by 30 per cent among eligible patients. Broad licensing and regional production make treatment affordable in most nations within two years. Health systems that adopt it reduce avoidable hospital admissions by 15 per cent over five years and raise working-age participation. To capture the gain a nation must identify eligible patients, sustain primary care and change payment incentives. Longer healthy lives alter pension and workforce assumptions. Providers that depend on treating preventable complications lose revenue, and populations that primary care does not reach fall further behind.

Who gains: People with or at high risk of cardiovascular disease, type 2 diabetes and kidney disease
Health systems with strong primary care and patient registers
Employers and public finances, through fewer absences and higher working-age participation
Generic and regional medicines manufacturers holding licences
Unpaid carers, most of them women, released from caring for relatives with complications
Who loses: Hospitals and specialist providers paid by the admission or procedure for preventable complications
Dialysis operators and suppliers of devices and medicines for late-stage disease
Originator firms whose branded metabolic medicines lose pricing power
Pension funds, annuity providers and ageing states that priced on shorter lives
Populations without access to primary care, who fall further behind

A shock most would count as progress. It is not upside for everyone: each record names who gains and who loses. Impact levels measure the scale of change, in either direction, and loads mark the capabilities a nation needs in order to capture the gain or absorb the loss.

05Historical anchors

Event	Date	What happened	Calibrates
GLP-1 medicines	2021–2026	Demand outran supply for several years at prices beyond most health budgets. The SELECT trial, reported in 2023, found that semaglutide reduced major cardiovascular events by 20 per cent among 17,604 adults with overweight or obesity and established cardiovascular disease. Generic semaglutide launched in India in March 2026.	One metabolic medicine has already delivered two thirds of the assumed effect. Price and supply, not efficacy, held back scale.
Scandinavian Simvastatin Survival Study	1994	A trial of 4,444 patients with coronary heart disease found that simvastatin reduced deaths from all causes by 30 per cent over a median of 5.4 years. Statins later lost patent protection and became some of the most widely prescribed medicines in the world.	An effect of 30 per cent from a medicine that became cheap has a precedent. Population uptake took about two decades, not two years.
Cardiovascular polypill trials	2019–2023	The PolyIran trial of 6,838 adults found in 2019 that a four-drug polypill reduced major cardiovascular events by 34 per cent over five years. The SECURE trial of 2,499 patients after a heart attack found a 24 per cent reduction in 2022. The World Health Organization added polypills to its Model List of Essential Medicines in 2023.	The assumed effect sits inside trial results for low-cost combinations. Use stayed low after the trials: evidence alone does not produce adoption.
Egypt hepatitis C screening and treatment campaign	2018–2023	Egypt screened about 50 million adults in seven months from October 2018 and treated about four million people with locally made generic antivirals, at a small fraction of the US launch price of US$84,000 a course. The World Health Organization confirmed in 2023 that Egypt had reached gold tier status on the path to elimination.	Licensing, local production and mass identification of patients can be completed inside two years by a middle-income state that organises for it.
Combination antiretroviral therapy	1996 onward	Combination therapy turned HIV from a fatal condition into a chronic one in high-income nations from 1996. Originator prices stood above US$10,000 per patient per year until an Indian generic manufacturer offered triple therapy at US$350 in 2001. Access in Africa lagged by about a decade.	The access gap between nations when licensing and regional production come late. The scenario assumes that gap closes within two years.
WHO global report on hypertension	September 2023	The World Health Organization's first global report on hypertension estimated that about 1.3 billion adults had the condition, that nearly half did not know it and that about one in five had it under control, although effective generic medicines cost little.	Counter-anchor. Cheap and effective prevention already exists and is not delivered. Identification and primary care, not the medicine, set the size of the gain.

06Parameters

Shown at their preset values. Parameters are not adjustable in this release and nothing on this page is computed from them. Custom settings run (Phase B) but are labelled 'non-standard run' and excluded from comparisons.

Common variables at Standard Severe · read-only

1. Severity: major
severe (Standard Severe)
extreme
2. Duration (acute phase): 30 days
90 days
1 year
3 years
5 years (Standard Severe)
3. Onset pace: days
weeks
months (Standard Severe)
years
4. Warning time: none
days
months (Standard Severe)
5. Scope: national
regional
global (Standard Severe)
6. Origin: natural
accidental (Standard Severe)
adversarial (great power / neighbour / non-state)
negotiated
Standard Severe: accidental (scientific and commercial)
7. External support: full
partial (Standard Severe)
none
8. Concurrency: standalone (Standard Severe)
plus one named scenario
plus two
9. Policy response assumed: none (pure exposure)
current plans executed (Standard Severe)
best practice
10. Recovery horizon: months
years
structural (Standard Severe)

Scenario-specific parameters · read-only

Parameter	Default	Range or options	Note
Reduction in major cardiovascular and diabetes complications among eligible treated patients	30 per cent	15 to 40	Relative to usual care, as established by the trials.
Time from trial results to affordable supply in most nations	2 years	1 to 6	Set by licence terms, regulatory approval and regional production.
Monthly cost of treatment per patient in licensed markets	US$6	US$3 to US$30	Medicines and marker testing. Excludes the cost of consultations.
Share of eligible adults identified and on treatment after five years in adopting systems	60 per cent	20 to 80	The main determinant of the national gain. Set by registers, primary care staffing and payment.
Reduction in avoidable hospital admissions in adopting systems over five years	15 per cent	5 to 25	—
Share of adults aged 40 and over who are eligible	25 per cent	15 to 40	Depends on the marker thresholds that regulators adopt.
Gain in projected life expectancy at 60 in adopting nations after five years	1 year	0.5 to 2	Drives the revision of pension, annuity and long-term care liabilities.

07Transmission channels

1
Large trials confirm that the combination, given to patients selected by biomarkers, reduces major cardiovascular and diabetes complications by 30 per cent.
2
Rights holders grant broad non-exclusive licences. Regional manufacturers enter and the monthly cost falls to a level that public programmes and households can pay.
3
Health systems with patient registers and funded primary care identify eligible adults and start treatment. In systems without them, uptake follows the ability to pay.
4
Heart attacks, strokes, kidney failure and amputations fall among treated patients. Avoidable admissions fall 15 per cent over five years in adopting systems.
5
Fewer people leave work through illness or to give care. Working-age participation and employment-linked revenue rise.
6
Hospitals, dialysis operators and suppliers paid for treating complications lose volume. Payment systems that reward admissions slow the shift of budgets to prevention.
7
Mortality assumptions are revised. Pension, annuity and long-term care liabilities rise and governments reopen pension age and contribution rules.
8
Differences in outcomes between and within nations widen and become a measure of government performance.

08Capability loading

High: capability band shifts expected under current plans. Medium: band shifts under 'none' policy response only. Low: strain without band shift. Loads are judgement-based until the Atlas connects. Domains link to the Atlas.

Domain	Load	Channel
Hard
Defence and security	Low	fitter recruitment pool and fewer medical discharges; no direct effect on force structure
Strategic infrastructure	Medium	primary care sites, laboratories and medicine distribution carry the roll-out; hospital capacity is repurposed
Critical technology	High	medicines manufacturing, biomarker diagnostics, clinical decision software and regulatory science
Soft
Government effectiveness	High	licence terms, procurement, patient registers and payment reform decide whether the gain is captured
Human capital	High	healthy life years, working-age participation and the supply of primary care staff
Influence and cohesion	Medium	unequal access within nations; licence terms and supply become instruments of health diplomacy
Economic
Macro-financial	High	lower acute care costs and higher labour supply against larger pension and long-term care liabilities
Industry, trade and supply	Medium	generic and regional producers gain; branded metabolic medicines and complication-treatment industries contract
Energy and resources	Low	modest change in food demand where appetite-reducing treatments are widely used

09Stakeholders

Government: Exposure
Health budgets, payment systems, pension rules and the capacity of primary care to find and follow eligible patients
Actions
Secure licences, regulatory approval and supply early, through pooled procurement where the national market is small
Fund patient registers and pay primary care for patients kept well, not for admissions
Re-test pension, disability and long-term care projections on revised mortality assumptions
Watch
Share of eligible adults identified and on treatment, by district and income group
Avoidable admissions for diabetes and heart failure
Licence coverage and the lowest tender price achieved
Technology: Exposure
Medicines manufacturers, diagnostics makers and suppliers of clinical decision and monitoring software
Actions
Qualify regional production and marker testing to regulatory standard ahead of demand
Build decision support that works in clinics with few staff and intermittent connectivity
Keep exchange of patient data consent-based and auditable
Watch
Regulatory approvals of generic combinations and marker panels
Supply of active pharmaceutical ingredients
Adherence rates recorded in monitoring systems
Investors: Exposure
Pension funds, annuity writers and health insurers repricing longevity and claims; hospital, dialysis and branded medicine revenues in decline; generic producers and primary care operators growing
Actions
Test pension and annuity books against faster mortality improvement at ages 50 to 80
Review holdings whose revenue depends on admissions and procedures for preventable complications
Assess sovereign exposure to age-related spending under longer lives
Watch
Mortality tables and the pricing of longevity risk transfers
Licence terms and patent expiry dates
Payment reform from fee-for-service to capitation or payment for outcomes
Public: Exposure
Access to testing and treatment through primary care; longer working lives and later pensions; fewer households providing care after a stroke or amputation
Actions
Take up testing where it is offered and ask which eligibility thresholds apply
Hold local health services to published uptake and outcome figures
Plan household finances for a longer working life
Watch
Coverage and co-payment decisions
Pension age proposals
Differences in uptake between districts and income groups

10Regional exposure

Region	Exposure	Rationale
North America	High	High obesity and diabetes prevalence and payment by the procedure: a large health gain and a large loss of provider revenue.
Europe	High	Strong primary care in many states supports capture; ageing populations make the pension revision large.
China	High	Very large diabetic and hypertensive population, domestic manufacturing and rapid ageing; hospital-centred care has to change.
Indo-Pacific	High	Japan and Korea face the sharpest longevity pressure; South-East Asian and Pacific states have rising diabetes and uneven primary care.
South Asia	High	Diabetes and heart disease strike early in working life; the generic manufacturing base supplies other regions.
Gulf and Middle East	High	Diabetes prevalence is some of the highest in the world; the means to pay exist but care is hospital-centred.
Africa	Medium	The burden is rising from a lower base in young populations; thin primary care and diagnostics limit capture.
Latin America and Caribbean	High	High obesity and diabetes, notably in Mexico; segmented health coverage decides who is reached.
Russia and Eurasia	High	High cardiovascular mortality among working-age men gives a large potential gain; primary care and access are weak.

11Early-warning indicators

Indicator	Source	Threshold
Results of cardiovascular and kidney outcome trials of oral and combination metabolic medicines	ClinicalTrials.gov; The New England Journal of Medicine; The Lancet	Two independent trials reporting a reduction of 25 per cent or more in major events
Voluntary licences for metabolic medicines and the countries they cover	Medicines Patent Pool; company licensing announcements	Non-exclusive licences covering more than 100 countries
Lowest monthly price of generic GLP-1 and SGLT2 medicines by country	PAHO Strategic Fund reference prices; national tender results	Below US$10 a month in most middle-income markets
Regulatory approvals of generic and combination metabolic medicines from regional producers	National regulators, including CDSCO in India, ANVISA in Brazil and SAHPRA in South Africa	—
Listing of combination and metabolic medicines as essential medicines	WHO Model List of Essential Medicines	Listing of the combination for primary prevention
Share of adults with hypertension and diabetes who are diagnosed, treated and controlled	WHO Global Health Observatory; NCD Risk Factor Collaboration	Control above 50 per cent of those with the condition
Avoidable hospital admissions for diabetes and congestive heart failure	OECD Health Statistics	A fall of more than 5 per cent in two years in an adopting system
Life expectancy at 60 and the mortality assumptions used by pension schemes	UN World Population Prospects; Human Mortality Database	Upward revision of half a year or more between editions

12Compounds

Triggers: S20 Outbreak defence succeeds · Licensing practice, regulatory reliance and regional medicines production built here raise readiness for a distributed outbreak response
S02 Global funding seizure · Longevity revisions add to the pension liabilities of ageing sovereigns; a contributing pressure, not a cause alone
Triggered by: S17 Automated discovery step · AI-directed research shortens the development of the combination and of the marker panel
S18 Public service leap · Identity and consent-based data exchange make patient registers and recall workable at national scale
S11 Debt service reset · Released fiscal capacity lets indebted states fund primary care and procurement
S20 Outbreak defence succeeds · Regional production, broad licensing and primary care delivery proven in the outbreak carry over to preventive treatments.
Patent expiry of leading metabolic medicines in major marketsA pooled procurement decision by several large public purchasers
Amplified by: S08 AI labour shock · The same low-cost AI agents support monitoring and recall where health workers are scarce
Amplifying trends: Biomarker-guided precision medicineAI drug developmentChronic disease & obesity burdenDigital & AI-supported careHealthy lifespan divergenceHealth workforce scarcityRegional medicines manufacturingAge-related fiscal liabilities
Key trends: Chronic disease & obesity burdenCritical Intellectual property access dependenceVery high Age-related fiscal liabilitiesVery high Biomarker-guided precision medicineVery high
From GINC Trends: the trends rated Very high or Critical for this scenario, of 250. All S19 trend scores.

13Rating rationale

Rating	Band or level	Why
Likelihood, two years	3Possible	The components exist. The SELECT trial showed a 20 per cent reduction in major cardiovascular events from one medicine in 2023 and polypill trials reported 24 and 34 per cent. Generic semaglutide launched in India in March 2026. The full event also needs confirmatory trials of a low-cost combination and licences covering most regions. Trials of that size rarely report and license within two years, which holds the rating at Possible.
Likelihood, ten years	4Likely	Over ten years the main patents on current metabolic medicines lapse in most large markets and outcome trials now in progress report. The precedent from statins, antiretrovirals and hepatitis C antivirals is that effective medicines become cheap within a decade of proof. The uncertain part is a combined effect of 30 per cent with selection by biomarkers, which keeps the rating at Likely and not higher.
Systemic impact	3Significant	Cardiovascular disease caused about 17.9 million deaths in 2019 on World Health Organization estimates, and more than 500 million adults live with diabetes on International Diabetes Federation estimates. A 30 per cent reduction in complications among treated patients, with 15 per cent fewer avoidable admissions and higher working-age participation, shifts health and labour capability in many nations. The output effect builds slowly and is partly offset by pension costs: Significant, not Major.
National impact	4Major	Scored on human welfare and essential services, the highest dimensions reached. In a highly exposed nation with a heavy cardiometabolic burden and working primary care, heart attacks, strokes, kidney failure and amputations fall by close to a third among treated patients and hospital demand is restructured. Pension and care assumptions are reset. The change is Major but leaves the structure of the economy intact.
Confidence	low	Trial evidence supports the effect size, but adherence, uptake and the speed of licensing are uncertain. One panel member rated two-year likelihood a band lower and systemic impact a level higher.

Source of scores: model-panel-v0.5. Confidence refers to the rating, not the scenario. Calibration sources are listed with the anchors above and on the scenario methodology page.

14Open questions

Contested assumptions for the panel to resolve.

Whether an onset of months is right. Trial results and licences arrive within months, but the 15 per cent fall in admissions takes five years: the record may describe a shock followed by a trend.
How to score a nation where the treatment is licensed and affordable but primary care cannot identify or follow patients: as failing to gain, or as losing ground to its neighbours.
Whether longer healthy lives count as a load on macro-financial capability or a gain to it, given that pension liabilities and labour supply both rise.
Africa is rated Medium on present burden and age structure. That may understate exposure where diabetes and hypertension are rising fastest and are mostly undiagnosed.

15Commentary

No signed commentary in this build.

16Version and citation

Version: 0.5.0 · active · chronic-disease-advance
Change log: 0.5.0 · 9 October 2026 · Rebuilt in the second pass from Biomedical breakthrough wave: narrowed to low-cost prevention of cardiovascular and metabolic disease, with onset moved from years to months, regional exposure revised and the HIV, malaria and cancer vaccine elements removed.
Full change log

Rating history

One row per edition. Each edition page is frozen at release; corrections are published as errata.

Edition	Rank	L2y	L10y	Systemic	National	Confidence	Edition view
2027	Not ranked	3Possible	4Likely	3Significant	4Major	low	Open

Versions

Version	Date	Change
0.5.0	9 October 2026	Rebuilt in the second pass from Biomedical breakthrough wave: narrowed to low-cost prevention of cardiovascular and metabolic disease, with onset moved from years to months, regional exposure revised and the HIV, malaria and cancer vaccine elements removed.

Citation and downloads

Cite as

GINC (2027). Scenario S19 Affordable preventive treatments reduce chronic illness, Scenario Library v0.5. scenarios.ginc.org/scenarios/chronic-disease-advance

Content and data are published under CC BY 4.0.

Download JSON Download CSV